Get started
Author

Marilyn Tabachri

Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial
2024 · Eunice S Wang, Ghayas C Issa, et al. · The Lancet Oncology · 119
Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
2022 · Harry P. Erba, Amir T. Fathi, et al. · Blood · 70
Ziftomenib in Relapsed or Refractory NPM1 -Mutated AML
2025 · Eunice S. Wang, Pau Montesinos, et al. · Journal of Clinical Oncology · 48
P504: Updated Data for Ziftomenib in Patients With Npm1-mutated Relapsed or Refractory Acute Myeloid Leukemia
2023 · Amir Fathi, Eunice Wang, et al. · HemaSphere · 14
Pharmacokinetics and ADME Characterization After Oral and Intravenous Administration of [ 14C ]‐Ziftomenib in Healthy Male Participants
2025 · Amitava Mitra, Julie Mackey Ahsan, et al. · Clinical and Translational Science · 9
PDF
AML-475 Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML
2023 · Harry Erba, Eunice Wang, et al. · Clinical Lymphoma Myeloma & Leukemia · 9
Mogamulizumab within 55 Days of Allogeneic Transplant: A Report of 3 Cases
2019 · Mary Jo Lechowicz, Dolores Caballero, et al. · Blood · 3
A Practical Alternative to Refine the Estimate of fmCYP3A4 and Evaluate Drug–Drug Interaction Potential for Ziftomenib Using PBPK Modeling to Inform Labeling
2026 · Ian E. Templeton, Chara Litou, et al. · CPT Pharmacometrics & Systems Pharmacology
PDF
POSTER: AML-475 Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML
2023 · Harry Erba, Eunice Wang, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 9
Citation count: 270
H-index: 6
I10-index: 4
Year
Topic
Type